Sažetak sa skupa
https://doi.org/10.33004/reumatizam-supp-71-1-20
Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports
Filip Mirić
*
Srđan Novak
* Dopisni autor.
Puni tekst: hrvatski pdf 650 Kb
str. 22-23
preuzimanja: 52
citiraj
APA 6th Edition
Mirić, F. i Novak, S. (2024). Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports. Reumatizam, 71 (Supp 1). https://doi.org/10.33004/reumatizam-supp-71-1-20
MLA 8th Edition
Mirić, Filip i Srđan Novak. "Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports." Reumatizam, vol. 71, br. Supp 1, 2024 https://doi.org/10.33004/reumatizam-supp-71-1-20. Citirano 27.12.2024.
Chicago 17th Edition
Mirić, Filip i Srđan Novak. "Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports." Reumatizam 71, br. Supp 1 https://doi.org/10.33004/reumatizam-supp-71-1-20
Harvard
Mirić, F., i Novak, S. (2024). 'Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports', Reumatizam, 71(Supp 1). https://doi.org/10.33004/reumatizam-supp-71-1-20
Vancouver
Mirić F, Novak S. Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports. Reumatizam [Internet]. 2024 [pristupljeno 27.12.2024.];71(Supp 1). https://doi.org/10.33004/reumatizam-supp-71-1-20
IEEE
F. Mirić i S. Novak, "Combination of rituximab and tofacitinib IN THE TREATMENT of anti-MDA 5 antibody positive dermatomyositis – case reports", Reumatizam, vol.71, br. Supp 1, 2024. [Online]. https://doi.org/10.33004/reumatizam-supp-71-1-20
Sažetak
Ključne riječi
Hrčak ID:
322089
URI
https://hrcak.srce.hr/322089
Datum izdavanja:
24.10.2024.
Podaci na drugim jezicima:
hrvatski
Posjeta: 128
*